Balyasny Asset Management’s Praxis Precision Medicines PRAX Stock Holding History

Balyasny Asset Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-369,254	Closed	-$15.5M	–	3363
2025 Q2	$15.5M	Sell	369,254 -33,749	-8%	-$1.29M	0.02%	771
2025 Q1	$15.3M	Buy	+403,003	New	+$25.2M	0.03%	710
2024 Q2	–	Sell	-13,311	Closed	-$812K	–	2990
2024 Q1	$812K	Buy	+13,311	New	+$597K	﹤0.01%	1876
2023 Q3	–	Sell	-688	Closed	-$11.9K	–	2627
2023 Q2	$11.9K	Buy	+688	New	+$10.5K	﹤0.01%	2172
2022 Q4	–	Sell	-1,671	Closed	-$57K	–	3140
2022 Q3	$57K	Buy	+1,671	New	+$83.3K	﹤0.01%	2462

Other funds holding PRAX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Balyasny Asset Management's PRAX Position: Q3 2025 in Review

Balyasny Asset Management sold out of Praxis Precision Medicines (PRAX) in Q3 2025, closing a stake of 369,254 shares — an estimated $15.5M sold.

Balyasny Asset Management first reported a position in PRAX in Q3 2022 and held it in 5 quarters. The position peaked at $15.5M in Q2 2025. 152 funds tracked by Wall St. Rank hold PRAX as of Q3 2025.

Balyasny Asset Management reported no remaining Praxis Precision Medicines position as of Q3 2025 after selling out during the quarter.
Balyasny Asset Management sold 369,254 Praxis Precision Medicines shares in Q3 2025, an estimated $15.5M.
Balyasny Asset Management first reported a position in Praxis Precision Medicines in Q3 2022 and held it in 5 quarters.
Balyasny Asset Management's Praxis Precision Medicines position peaked at $15.5M in Q2 2025.
152 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2025.

Based on Balyasny Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.